专注高品质产品
造福广大患者
Focusing on high-quality products
Benefiting the vast number of patients
Company Profile
公司介绍

JIANGSU BIODA LIFE SCIENCE Co., LTD. was established in 2015, and currently has two production and R&D bases in Shanghai and Nantong, with more than 200 employees. At the beginning of 2022, BIODA Life science Park in Nantong North High-tech City, covering an area of 25,000 square meters, started construction. The first phase of the 15,000-square-meter vascular graft production plant was put into operation in December 2022. The company has set up an R&D center in Shanghai Zhangjiang Medical Valley, which has been stationed in October 2022. R&D center laboratory covers an area of 6,500 square meters, which can meet the development and production of a variety of products.

 

Since its establishment, BIODA and its subsidiaries have won the innovation fund support of Shanghai “Science and technology Innovation Action Plan” and the Outstanding Enterprise Award of “Enterpreneurship in Shanghai” International Innovation and Entrepreneurship Competition for many times. It was awarded into the “high-tech Enterprise Cultivation Pool” of Jiangsu Province, and won the title of “National high-tech Enterprise”.

 

VASOLINE®️ vascular graft was approved by NMPA on November 6, 2022 (NMPA 20223131515); Dialysis vascular prosthesis is currently in the clinical trial stage, and the product has been praised by doctors for its high quality. In China, VASOLINEE®️ ️vascular graft is the first and only one approve vascular graft brand.

 

At present, the company has more than 20 research projects, covering cardiovascular surgery,  vascular surgery, cardiac surgery, general surgery and other departments. Relying on the technology platform of polymer materials, biological materials and metal scaffold molding, BIODA is constantly introducing more high-quality products for clinical needs to benefit the majority of patients.

corporate culture
企业文化
development history
发展历程
Honors and Patents
荣誉及专利
3.231261s